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LETTERS
Ceftriaxone-
Resistant Neisseria 
gonorrhoeae, Japan
To the Editor: Spread of multi-
drug-resistant Neisseria gonorrhoeae 
is a major public health concern. Ef-
fective antimicrobial therapy is a key 
element in gonorrhea control. How-
ever,  N. gonorrhoeae has developed 
resistance to multiple classes of anti-
microbial drugs, including β-lactams, 
tetracyclines, and ﬂ  uoroquinolones 
(1–3). Even an extended-spectrum 
oral cephalosporin-resistant, ceﬁ  xime-
resistant N. gonorrhoeae has emerged, 
and ceﬁ  xime has now been withdrawn 
from use in Japan. Best practice treat-
ment is limited to injectable extend-
ed-spectrum cephalosporins, such as 
ceftriaxone and spectinomycin. The 
emergence of ceftriaxone-resistant N. 
gonorrhoeae threatens effective dis-
ease control.
We identiﬁ   ed a novel ceftriax-
one-resistant N. gonorrhoeae isolated 
from a 31-year-old female commer-
cial sex worker; MIC of ceftriaxone 
for this isolate was high (2 μg/mL). 
The woman visited a clinic in Kyoto 
for a routine examination for sexu-
ally transmitted infections in January 
2009. Although she had no obvious 
symptoms or signs, a throat sample 
collected on her ﬁ  rst visit yielded a 
positive result for N. gonorrhoeae by 
the strand displacement ampliﬁ  cation 
test (ProbeTec ET, Becton Dickinson, 
Franklin Lakes, NJ, USA), but a vagi-
nal sample taken at the same time was 
negative. After 2 weeks, another throat 
sample was positive for N. gonorrhoe-
ae when cultured on Thayer-Martin 
medium, and the patient subsequently 
received 1 g ceftriaxone intravenous-
ly. Her pharyngeal sample was also 
N. gonorrhoeae positive by strand 
displacement ampliﬁ  cation test on the 
third visit 2 weeks later, and further 
ceftriaxone treatment was prescribed. 
However, a culture for test of cure was 
not conducted because reinfection was 
considered. A negative result was ﬁ  -
nally obtained in April 2009.
The culture showed positive re-
actions in oxidase and catalase tests. 
Gram staining showed gram-negative 
diplococci. The ID-test HN-20 Rapid 
system (Nissui, Tokyo, Japan) classi-
ﬁ  ed the bacterium as N. gonorrhoeae. 
Susceptibility was determined by the 
agar dilution method (4). For this strain, 
named H041, MIC of ceftriaxone was 
high (2 μg/mL), and the strain was 
highly resistant to penicillin G (4 μg/
mL), ceﬁ  xime (8 μg/mL), and levoﬂ  ox-
acin (32 μg/mL). However, it demon-
strated susceptibility to spectinomycin 
(16 μg/mL) and reduced susceptibility 
to azithromycin (0.5 μg/mL).
To characterize the ceftriaxone-
resistant N. gonorrhoeae H041, mul-
tilocus sequence typing characterized 
the strain as ST7363 (5), which is 
the predominant sequence type (ST) 
among ceﬁ   xime-resistant clones (6). 
N. gonorrhoea multiantigen sequence 
typing (NG-MAST) was also per-
formed (7). The NG-MAST strategy 
uses 2 genes, por and tbpB, for porin 
and a transferrin-binding protein, re-
spectively. NG-MAST indicated that 
the strain H041 was ST4220 and 
contained the por2594 allele and the 
tbpB10 allele. NG-MAST 4220 is a 
novel ST. However, the tbpB10 allele 
is the most frequently observed allele 
(76.5%) among multilocus sequence 
typing-ST7363 N. gonorrhoeae strains 
(n = 81) (M. Ohnishi, unpub. data).
Molecular typing suggested that 
the novel ceftriaxone-resistant N. gon-
orrhoeae, H041, is closely related to 
the ST7363 ceﬁ  xime-resistant N. gon-
orrhoeae. Therefore, we compared 
SpeI-digested genomic DNA banding 
patterns of strain H041 with those of 
other  N. gonorrhoeae strains by us-
ing pulsed-ﬁ  eld gel electrophoresis as 
described (8). Four ST7363 strains, 
including N. gonorrhoeae H041, and 
4 ST1901 strains (another major ST 
among ceﬁ  xime-resistant  N. gonor-
rhoeae strains) (6) were analyzed. 
The banding pattern of SpeI digested 
H041 genomic DNA was similar to 
that of other ST7363 strains and in-
distinguishable from that of ceﬁ  xime-
resistant but ceftriaxone-susceptible 
NG0207 (Figure).
We describe the emergence of 
ceftriaxone-resistant N. gonorrhoeae, 
isolated from a pharyngeal specimen 
from a female commercial sex work-
er. At 2 μg/mL, the MIC was 4-fold 
higher than that of the previously 
reported ceftriaxone nonsusceptible 
strain (9). Our susceptibility testing 
suggests that only azithromycin and 
spectinomycin are effective drugs 
for treating this strain. In this case, 
eradication was successful, although 
N. gonorrhoeae colonization of the 
pharynx may just be tempory because 
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Figure. Pulsed-ﬁ   eld gel electrophoresis patterns of ceftriaxone-resistant Neisseria 
gonorrhoeae strain H041 and other multilocus sequence typing (MLST) ST7363 and 
ST1901 strains. SpeI-digested genomic DNA from ceftriaxone-resistant N. gonorrhoeae 
H041, 3 of the MLST ST7363 strains and 4 of the MLST ST1901 strains were analyzed by 
pulsed-ﬁ  eld gel electrophoresis. A lambda ladder standard (Bio-Rad, Hercules, CA, USA) 
was used as a molecular size marker.LETTERS
the pharynx is not an ideal site for N. 
gonorrhoeae growth. From the rou-
tine examinations of commercial sex 
workers during January–March 2009, 
40 N. gonorrhoeae were isolated in 
the clinic, but no other ceftriaxone-
resistant strains were isolated. There 
is no evidence of dissemination of 
this strain in Kyoto.
Three independent molecular 
subtyping methods indicated that the 
ceftriaxone-resistant H041 strain was 
N. gonorrhoeae, and it might originate 
from an ST7363 ceﬁ  xime-resistant N. 
gonorrhoeae clone. There are several 
possible mechanisms for the acquisi-
tion of resistance, including formation 
of a new mosaic type penA allele as 
penA-X ceﬁ   xime resistance and ac-
quisition of an extended-spectrum 
β-lactamase gene. The H041 strain did 
not produce β-lactamase in a nitroce-
phin test. Further molecular analysis is 
needed to elucidate the precise mecha-
nism of the ceftriaxone resistance of 
the H041 strain.
The emergence of ceftriaxone-re-
sistant N. gonorrhoeae raises concerns 
for controlling gonorrhea because cef-
triaxone is widely recommended and 
the ﬁ  rst-line treatment for gonorrhea 
around the world. N. gonorrhoeae has 
a potential to gain an extraordinarily 
high MIC to ceftriaxone. Surveillance 
for ceftriaxone-resistant N.  gonor-
rhoeae should be strengthened.
Acknowledgment
We thank Hiroko Matsuoka for her 
technical assistance.
This study was supported by grants-
in-aid from the Ministry of Health, Labour 
and Welfare of Japan (H21-Shinko-Ippan-
001, and −012).
Makoto Ohnishi, Takeshi Saika, 
Shinji Hoshina, 
Kazuhiro Iwasaku, 
Shu-ichi Nakayama, 
Haruo Watanabe, 
and Jo Kitawaki
Author afﬁ   liations: National Institute of In-
fectious Diseases, Tokyo, Japan (M. Ohni-
shi, S. Nakayama, H. Watanabe); Mitsubi-
shi Chemical Medience Corporation, Tokyo 
(T. Saika); Hoshina Clinic, Kyoto, Japan 
(S. Hoshina); and Kyoto Prefectural Uni-
versity of Medicine, Kyoto (K. Iwasaku, J. 
Kitawaki)
DOI: 10.3201/eid1701.100397
References
  1.   Tapsall JW, Ndowa F, Lewis DA, Unemo 
M. Meeting the public health challenge 
of multidrug- and extensively drug-resis-
tant  Neisseria gonorrhoeae. Expert Rev 
Anti Infect Ther. 2009;7:821–34. DOI: 
10.1586/eri.09.63
    2.   Workowski KA, Berman SM, Douglas 
JM Jr. Emerging antimicrobial resistance 
in Neisseria gonorrhoeae: urgent need to 
strengthen prevention strategies. Ann In-
tern Med. 2008;148:606–13.
    3.    Tapsall J. Antibiotic resistance in Neis-
seria gonorrhoeae is diminishing avail-
able treatment options for gonorrhea: 
some possible remedies. Expert Rev 
Anti Infect Ther. 2006;4:619–28. DOI: 
10.1586/14787210.4.4.619
  4.   Clinical  Laboratory  Standards  Institute. 
Performance standards for antimicrobial 
susceptibility testing, 19th informational 
supplement. CLSI document M100–S19. 
Wayne (PA): The Institute; 2009.
    5.   Jolley KA. Multi-locus sequence typ-
ing. In: Pollard AJ Maiden MCJ, editors. 
Meningococcal disease: methods and pro-
tocols. Totowa (NJ): Humana Press; 2001. 
p. 173–86.
  6.   Ohnishi  M,  Watanabe  Y,  Ono  E,  Taka-
hashi C, Oya H, Kuroki T, et al. Spread-
ing of a chromosomal ceﬁ  xime resistant 
penA gene among different Neisseria 
gonorrhoeae lineages. Antimicrob Agents 
Chemother. 2010;54:1060–7. DOI: 
10.1128/AAC.01010-09
  7.   Martin IM, Ison CA, Aanensen DM, Fen-
ton KA, Spratt BG. Rapid sequence-based 
identiﬁ  cation of gonococcal transmission 
clusters in a large metropolitan area. J 
Infect Dis. 2004;189:1497–505. DOI: 
10.1086/383047
  8.   Ito M, Yasuda M, Yokoi S, Ito S, Taka-
hashi Y, Ishihara S, et al. Remarkable 
increase in central Japan in 2001–2002 
of  Neisseria gonorrhoeae isolates with 
decreased susceptibility to penicillin, tet-
racycline, oral cepharosporins, and ﬂ  uo-
roquinolones. Antimicrob Agents Chemo-
ther. 2004;48:3185–7. DOI: 10.1128/AAC.
48.8.3185-3187.2004
    9.   Tanaka M, Nakayama H, Huruya K, 
Konomi I, Irie S, Kanayama A, et al. 
Analysis of mutations within multiple 
genes associated with resistance in a clini-
cal isolate of Neisseria gonorrhoeae with 
reduced ceftriaxone susceptibility that 
shows a multidrug-resistant phenotype. 
Int J Antimicrob Agents. 2006;27:20–6. 
DOI: 10.1016/j.ijantimicag.2005.08.021
Address for correspondence: Makoto Ohnishi, 
Department of Bacteriology I, National 
Institute of Infectious Diseases, 1-23-1 Toyama, 
Shinjuku, Tokyo 162-8640, Japan, email: 
ohnishi7@nih.go.jp
Role of National 
Travel Health 
Network and 
Centre Website 
during Pandemic 
(H1N1) 2009
To the Editor: The National 
Travel Health Network and Centre 
(NaTHNaC) was created in 2002 by 
the Department of Health in England 
to provide authoritative guidance in 
travel medicine. The open-access 
NaTHNaC website (www.nathnac.
org) is a key mode of communication, 
with both health professionals’ and 
travelers’ areas. Website country in-
formation pages (CIP) provide specif-
ic guidance for travel to each country 
of the world, and an outbreak surveil-
lance database (OSD) detailing global 
outbreaks of disease is updated daily.
In late April 2009, inﬂ  uenza A vi-
rus (H1N1) of swine origin was iden-
tiﬁ   ed in 2 children from California, 
USA (1). These cases were traced to 
travel to Mexico, and a widespread 
outbreak of inﬂ   uenza A (H1N1) in 
Mexico subsequently was recognized. 
On June 11, 2009, the World Health 
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